Comparative Pharmacology
Head-to-head clinical analysis: ALPHAREDISOL versus DODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAREDISOL versus DODEX.
ALPHAREDISOL vs DODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyanocobalamin (vitamin B12) acts as a cofactor for methionine synthase and L-methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis. Alpharedisol is a cyanocobalamin formulation that corrects vitamin B12 deficiency.
Hydroxocobalamin is a synthetic form of vitamin B12, which acts as a cofactor for methionine synthase and methylmalonyl-CoA mutase, essential for DNA synthesis, myelin formation, and hematopoiesis.
Hydroxocobalamin 1 mg intramuscularly once daily for 5-10 days, then 1 mg once monthly for life.
1 mg intramuscularly once every 7-10 days for maintenance; 1 mg intramuscularly once daily for 7 days for initial treatment.
None Documented
None Documented
1.5 hours in healthy adults; prolonged to 3-6 hours in renal impairment
Terminal elimination half-life is approximately 6 days (range 4-10 days) in plasma; however, due to extensive tissue binding and enterohepatic recirculation, the pharmacodynamic half-life for correction of deficiency is about 1 year.
Renal (90% as unchanged drug); biliary/fecal (10%)
Primarily renal: ~50-80% of absorbed dose excreted unchanged in urine via glomerular filtration. Biliary/fecal excretion accounts for <10% as cyanocobalamin.
Category C
Category C
Vitamin B12 Supplement
Vitamin B12 Supplement